Dr. Greg Bailey, MD
Chief Executive Officer, Juvenescence
Juvenescence will be an innovative 21st century biotech company. We will focus on the disruptive technologies to prevent or delay age-related disease and modify aging. We’ll incorporate machine learning, social media and a direct relationship with our patients and consumers to empower and facilitate healthy longer life.
Dr. Greg Bailey, MD, a co-founder and the CEO of Juvenescence, is a physician, financier and biotech entrepreneur with extensive experience founding and financing healthcare companies.
Dr. Bailey is driven by the important opportunity to truly modify aging based on rigorous science. The goal: to use his track record and drug development expertise, and that of his partners, to find compelling products and raise the extraordinary amount of money necessary to fulfill the promise of Juvenescence.
Dr. Bailey is also the chairman of Portage Biotech, Inc. (PTGEF: OTCBB), a publicly-traded oncology drug development company. He was a former managing partner of Palantir Group, Inc., a merchant bank specializing in biotech and intellectual property and he was the initial financier and an independent director of Medivation, Inc. (MDVN:NASDAQ), acquired by Pfizer in 2016. He also led the seed financing of Biohaven Pharmaceuticals Holding Company Ltd. and joined the board in 2014.
Previously he founded or financed Ascent Healthcare Solutions, VirnetX Inc. (VHC:AMEX), and SalvaRx Group PLC. Dr. Bailey has an MD from the University of Western Ontario and practiced emergency medicine for 10 years prior to becoming a serial entrepreneur.
Greg has embraced a healthy lifestyle that includes biohacking, proper diet and a comprehensive exercise program: high intensity training, weightlifting, aerobic exercise and yoga.